In a filing, Cullinan Therapeutics Inc revealed its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.33 million on Oct 16 ’25. In the deal valued at $8.86 per share,150,000 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 8,765,616 shares worth roughly $70.65 million.
Then, Lynx1 Capital Management LP bought 51,500 shares, generating $409,049 in total proceeds. Upon buying the shares at $7.94, the 10% Owner now owns 8,615,616 shares.
Before that, Lynx1 Capital Management LP bought 32,217 shares. Cullinan Therapeutics Inc shares valued at $252,565 were divested by the 10% Owner at a price of $7.84 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 8,797,833 shares, worth roughly $70.91 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Monday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock jump 3.87% to $8.06. Over the last five days, the stock has lost -5.84%. Cullinan Therapeutics Inc shares have fallen nearly -48.37% since the year began. Nevertheless, the stocks have fallen -33.83% over the past one year. While a 52-week high of $17.50 was reached on 01/03/25, a 52-week low of $5.68 was recorded on 10/03/25.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 7.80, which if violated will result in even more drops to 7.54. On the upside, there is a resistance level at 8.36. A further resistance level may holdings at 8.66.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-10-15, growing by 0.45 million shares to a total of 6.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 6.18 million shares. There was a rise of 6.77%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
